On-demand therapy is a valid strategy in GERD patients: Pros and cons

Digestive Diseases

Volumn 25, Issue 3, 2007, Pages 175-178

  Leodolter, Andreas ^a   Penagini, Roberto ^b,c  

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITY OF MILAN   (Italy)

^c FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

Gastroesophageal reflux disease; On demand GERD therapy, pros and cons; On demand GERD treatment; Proton pump inhibitors

Indexed keywords

ANTACID AGENT; PROTON PUMP INHIBITOR; ENZYME INHIBITOR; HYDROGEN POTASSIUM ADENOSINE TRIPHOSPHATASE;

BARRETT ESOPHAGUS; CONFERENCE PAPER; COST CONTROL; DATA ANALYSIS; DISEASE SEVERITY; DRUG EFFICACY; DRUG UTILIZATION; DYSPLASIA; ESOPHAGITIS; ESOPHAGUS; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL HEMORRHAGE; HEARTBURN; HUMAN; PRIORITY JOURNAL; STOMACH ACID; AGED; ARTICLE; DRUG ANTAGONISM; REFLUX ESOPHAGITIS;

AGED; BARRETT ESOPHAGUS; ENZYME INHIBITORS; ESOPHAGITIS, PEPTIC; GASTROESOPHAGEAL REFLUX; H(+)-K(+)-EXCHANGING ATPASE; HUMANS;

EID: 35449003686     PISSN: 02572753     EISSN: None     Source Type: Journal    
DOI: 10.1159/000103880     Document Type: Conference Paper

References (31)

1. Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R: The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol 2006;101:1900-1920.
2. Quigley EM: Non-erosive reflux disease: part of the spectrum of gastro-oesophageal reflux disease, a component of functional dyspepsia, or both? Eur J Gastroenterol Hepatol 2001;13(suppl 1):S13-S18.
3. Bytzer P, Blum A, De Herdt D, Dubois D: Six-month trial of on-demand rabeprazole 10 mg maintains symptom relief in patients with non-erosive reflux disease. Aliment Pharmacol Ther 2004;20:181-188.
4. Kaspari S, Kupcinskas L, Heinze H, Berghofer P: Pantoprazole 20 mg on demand is effective in the long-term management of patients with mild gastro-oesophageal reflux disease. Eur J Gastroenterol Hepatol 2005;17:935-941.
5. Lind T, Havelund T, Lundell L, Glise H, Lauritsen K, Pedersen SA, Anker-Hansen O, Stubberod A, Eriksson G, Carlsson R, Junghard O: On-demand therapy with omeprazole for the long-term management of patients with heartburn without oesophagitis - a placebo-controlled randomized trial. Aliment Pharmacol Ther 1999;13:907-914.
6. Scholten T, Dekkers CP, Schutze K, Korner T, Bohuschke M, Gatz G: On-demand therapy with pantoprazole 20 mg as effective long-term management of reflux disease in patients with mild GERD: the ORION trial. Digestion 2005;72:76-85.
7. Talley NJ, Lauritsen K, Tunturi-Hihnala H, Lind T, Moum B, Bang C, Schulz T, Omland TM, Delle M, Junghard O: Esomeprazole 20 mg maintains symptom control in endoscopy-negative gastro-oesophageal reflux disease: a controlled trial of 'on-demand' therapy for 6 months. Aliment Pharmacol Ther 2001;15:347-354.
8. Talley NJ, Venables TL, Green JR, Armstrong D, O'Kane KP, Giaffer M, Bardhan KD, Carlsson RG, Chen S, Hasselgren GS: Esomeprazole 40 mg and 20 mg is efficacious in the long-term management of patients with endoscopy-negative gastro-oesophageal reflux disease: a placebo-controlled trial of on-demand therapy for 6 months. Eur J Gastroenterol Hepatol 2002;14:857-863.
9. Norman Hansen A, Bergheim R, Fagertun H, Lund H, Moum B: A randomised prospective study comparing the effectiveness of esomeprazole treatment strategies in clinical practice for 6 months in the management of patients with symptoms of gastroesophageal reflux disease. Int J Clin Pract 2005;59:665-671.
10. Tsai HH, Chapman R, Shepherd A, McKeith D, Anderson M, Vearer D, Duggan S, Rosen JP: Esomeprazole 20 mg on-demand is more acceptable to patients than continuous lansoprazole 15 mg in the long-term maintenance of endoscopy-negative gastro-oesophageal reflux patients: the COMMAND Study. Aliment Pharmacol Ther 2004;20:657-665.
11. Sjostedt S, Befrits R, Sylvan A, Harthon C, Jorgensen L, Carling L, Modin S, Stubberod A, Toth E, Lind T: Daily treatment with esomeprazole is superior to that taken on-demand for maintenance of healed erosive oesophagitis. Aliment Pharmacol Ther 2005;22:183-191.
12. Norman Hansen A, Wahlqvist P, Jorgensen E, Bergheim R, Fagertun H, Lund H, Moum B: Six-month management of patients following treatment for gastroesophageal reflux disease symptoms - a Norwegian randomized, prospective study comparing the costs and effectiveness of esomeprazole and ranitidine treatment strategies in a general medical practitioners setting. Int J Clin Pract 2005;59:655-664.
13. Bytzer P, Blum AL: Personal view: rationale and proposed algorithms for symptombased proton pump inhibitor therapy for gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2004;20:389-398.
14. Labenz J, Nocon M, Lind T, Leodolter A, Jaspersen D, Meyer-Sabellek W, Stolte M, Vieth M, Willich SN, Malfertheiner P: Prospective follow-up data from the ProGERD study suggest that GERD is not a categorial disease. Am J Gastroenterol 2006;101:2457-2462.
15. Sontag SJ, Sonnenberg A, Schnell TG, Leya J, Metz A: The long-term natural history of gastroesophageal reflux disease. J Clin Gastroenterol 2006;40:398-404.
16. Jacobson BC, Ferris TG, Shea TL, Mahlis EM, Lee TH, Wang TC: Who is using chronic acid suppression therapy and why? Am J Gastroenterol 2003;98:51-58.
17. Van Soest EM, Siersema PD, Dieleman JP, Sturkenboom MC, Kuipers EJ: Persistence and adherence to proton pump inhibitors in daily clinical practice. Aliment Pharmacol Ther 2006;24:377-385.
18. Hungin AP, Rubin GP, O'Flanagan H: Long-term prescribing of proton pump inhibitors in general practice. Br J Gen Pract 1999;49:451-453.
19. Hungin AP, Rubin G, O'Flanagan H: Factors influencing compliance in long-term proton pump inhibitor therapy in general practice. Br J Gen Pract 1999;49:463-464.
20. Jones R, Armstrong D, Malfertheiner P, Ducrotte P: Does the treatment of gastroesophageal reflux disease meet patients' needs? A survey-based study. Curr Med Res Opin 2006;22:657-662.
21. Cederberg C, Thomson AB, Mahachai V, Westin JA, Kirdeikis P, Fisher D, Zuk L, Marriage B: Effect of intravenous and oral omeprazole on 24-hour intragastric acidity in duodenal ulcer patients. Gastroenterology 1992;103:913-918.
22. Juul-Hansen P, Rydning A: On-demand PPI requirements in patients with endoscopy-negative GERD. J Clin Gastroenterol 2004;38:746-749.
23. Bayerdorrfer E, Sipponen P, Bigard M, Weiss W, Mearin F, Rodrigo L: Esomeprazole 20 mg continuous versus on-demand treatment of patients with endoscopy-negative reflux disease. Gut 2004;53:A106.
24. Vakil NB, Shaker R, Johnson DA, Kovacs T, Baerg RD, Hwang C, D'Amico D, Hamelin B: The new proton pump inhibitor esomeprazole is effective as a maintenance therapy in GERD patients with healed erosive oesophagitis: a 6-month, randomized, double-blind, placebo-controlled study of efficacy and safety. Aliment Pharmacol Ther 2001;15:927-935.
25. Johnsson F, Moum B, Vilien M, Grove O, Simren M, Thoring M: On-demand treatment in patients with oesophagitis and reflux symptoms: comparison of lansoprazole and omeprazole. Scand J Gastroenterol 2002;37:642-647.
26. Collen MJ, Abdulian JD, Chen YK: Gastroesophageal reflux disease in the elderly: more severe disease that requires aggressive therapy. Am J Gastroenterol 1995;90:1053-1057.
27. Zimmerman J, Shohat V, Tsvang E, Arnon R, Safadi R, Wengrower D: Esophagitis is a major cause of upper gastrointestinal hemorrhage in the elderly. Scand J Gastroenterol 1997;32:906-909.
28. Fitzgerald RC, Omary MB, Triadafilopoulos G: Dynamic effects of acid on Barrett's esophagus. An ex vivo proliferation and differentiation model. J Clin Invest 1996;98:2120-2128.
29. Ouatu-Lascar R, Fitzgerald RC, Triadafilopoulos G: Differentiation and proliferation in Barrett's esophagus and the effects of acid suppression. Gastroenterology 1999;117:327-335.
30. El Serag HB, Aguirre TV, Davis S, Kuebeler M, Bhattacharyya A, Sampliner RE: Proton pump inhibitors are associated with reduced incidence of dysplasia in Barrett's esophagus. Am J Gastroenterol 2004;99:1877-1883.
31. Hillman LC, Chiragakis L, Shadbolt B, Kaye GL, Clarke AC: Proton-pump inhibitor therapy and the development of dysplasia in patients with Barrett's oesophagus. Med J Aust 2004;180:387-391.